Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 3/20 | 0.34 |
| ▸ | CNR2 | P34972 | 3/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13097159 | 0.92 | GABRA5 (0.37) | CYP2D6GABRA5DHODHCNR1CNR2 | |
| SCHEMBL13097050 | 0.91 | CYP2D6 (0.42) | CYP2D6GABRA5GRM4CNR1CNR2 | |
| SCHEMBL13096951 | 0.90 | CYP2D6 (0.46) | CYP2D6DHODHCNR1CNR2PARP14 | |
| SCHEMBL13106529 | 0.89 | GRM4 (0.34) | CYP2D6GRM4CYP2C9RORC | |
| SCHEMBL13096921 | 0.88 | GABRA5 (0.42) | CYP2D6GABRA5CNR1CNR2PARP14 | |
| SCHEMBL13097052 | 0.87 | CYP2D6 (0.39) | CYP2D6DHODHCNR1CNR2PARP14 | |
| SCHEMBL13097038 | 0.83 | CYP2D6 (0.40) | CYP2D6DHODHCNR1CNR2PARP14 | |
| SCHEMBL3098716 | 0.83 | PDE2A (0.39) | CYP2D6GABRA5CNR1CNR2PARP14 | |
| SCHEMBL13106534 | 0.82 | PDE2A (0.34) | CNR1CNR2MAPK14 | |
| SCHEMBL13096973 | 0.81 | CYP2D6 (0.47) | CYP2D6CNR1CNR2PARP14MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256113-A1 | QUINOLONE DERIVATIVE | NQO1, NQO2, NADK | CYP2D6 230/4885GABRA5 3532/4885GRM4 2798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.